Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,400 | 2 | 73.0% |
| Unspecified | $2,879 | 3 | 25.0% |
| Food and Beverage | $232.69 | 1 | 2.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $11,279 | 5 | $0 (2022) |
| Intuitive Surgical, Inc. | $232.69 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,725 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,725) |
| 2021 | $1,154 | 2 | Novartis Pharmaceuticals Corporation ($1,154) |
| 2020 | $8,400 | 2 | Novartis Pharmaceuticals Corporation ($8,400) |
| 2017 | $232.69 | 1 | Intuitive Surgical, Inc. ($232.69) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $1,725.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 06/09/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $204.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR PIQRAY RESEARCH • Category: ONCOLOGY | ||||||
| 01/05/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $950.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH • Category: ONCOLOGY | ||||||
| 11/10/2020 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 11/09/2020 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 06/13/2017 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $232.69 | General |
| Category: SURGERY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,725 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $950.00 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $204.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 166 | 243 | $40,694 | $6,733 |
| 2022 | 5 | 136 | 230 | $31,524 | $5,812 |
| 2021 | 6 | 114 | 172 | $7,330 | $4,990 |
| 2020 | 6 | 146 | 213 | $6,823 | $4,740 |
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 44 | 44 | $8,316 | $1,934 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 26 | 26 | $7,540 | $1,806 | 23.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 30 | 30 | $7,560 | $1,133 | 15.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 11 | 11 | $3,553 | $667.29 | 18.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2023 | 12 | 12 | $3,899 | $591.04 | 15.2% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 22 | 22 | $5,220 | $440.70 | 8.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 21 | 98 | $4,606 | $161.20 | 3.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 43 | 43 | $8,127 | $2,110 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 22 | 22 | $6,380 | $1,551 | 24.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 33 | 33 | $8,019 | $1,247 | 15.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 11 | 11 | $3,553 | $713.35 | 20.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 27 | 121 | $5,445 | $190.75 | 3.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 30 | 30 | $1,981 | $1,473 | 74.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 19 | $2,049 | $1,170 | 57.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $1,461 | $1,084 | 74.2% |
| 17000 | Destruction of skin growth | Facility | 2021 | 25 | 25 | $1,316 | $916.02 | 69.6% |
| 11102 | Tangential biopsy of single skin lesion | Facility | 2021 | 14 | 14 | $370.80 | $225.77 | 60.9% |
| 17003 | Destruction of 2-14 skin growths | Facility | 2021 | 15 | 73 | $153.30 | $121.10 | 79.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 52 | 52 | $2,755 | $2,031 | 73.7% |
| 17000 | Destruction of skin growth | Facility | 2020 | 28 | 28 | $1,422 | $879.55 | 61.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 12 | 12 | $1,134 | $699.71 | 61.7% |
| 17110 | Destruction of up to 14 skin growths | Facility | 2020 | 12 | 12 | $743.16 | $578.77 | 77.9% |
| 11102 | Tangential biopsy of single skin lesion | Facility | 2020 | 17 | 17 | $568.80 | $393.21 | 69.1% |
| 17003 | Destruction of 2-14 skin growths | Facility | 2020 | 25 | 92 | $199.64 | $158.35 | 79.3% |
About Dr. Megha Tollefson, M.D
Dr. Megha Tollefson, M.D is a Pediatrics healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689646093.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Megha Tollefson, M.D has received a total of $11,512 in payments from pharmaceutical and medical device companies, with $1,725 received in 2022. These payments were reported across 6 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($8,400).
As a Medicare-enrolled provider, Tollefson has provided services to 562 Medicare beneficiaries, totaling 858 services with total Medicare billing of $22,275. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Practice Information
- Specialty Pediatrics
- Other Specialties Dermatology
- Location Rochester, MN
- Active Since 02/02/2006
- Last Updated 08/21/2020
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1689646093
Products in Payments
- BYL719 (Drug) $8,400
- PIQRAY (Drug) $2,879
- Da Vinci Surgical System (Device) $232.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Rochester
Rachael Phelps, M.d, M.D
Pediatrics — Payments: $169,813
Partha Ghosh, Md, MD
Pediatrics — Payments: $99,006
Jason Anderson, Md, MD
Pediatrics — Payments: $61,051
Robert Jacobson, M.d, M.D
Pediatrics — Payments: $48,036
Fatima Ali-Ahmed, M.d, M.D
Pediatrics — Payments: $27,406
Samar Ibrahim, Mb, Chb, MB, CHB
Pediatrics — Payments: $26,378